Progression delay in men with mild symptoms of bladder outlet obstruction: a comparative study of phytotherapy and watchful waiting

被引:0
作者
Bob Djavan
Yan Kit Fong
Aziz Chaudry
Andreas Reissigl
Theodore Anagnostou
Fariborz Bagheri
Matthias Waldert
Sibylle Marihart
Mike Harik
Michael Marberger
机构
[1] University of Vienna,Department of Urology
[2] St Thomas Hospital,Department of Urology
[3] LKH Bregenz,Department of Urology
[4] Unversity Pecz,Department of Urology
来源
World Journal of Urology | 2005年 / 23卷
关键词
Benign prostatic hyperplasia; Progression; Watchful waiting; Placebo;
D O I
暂无
中图分类号
学科分类号
摘要
To determine the effect of phytotherapy (Serona repens) on the clinical progression in men with mild symptoms of bladder outlet obstruction (BOO). A total of 189 patients with mild symptoms of BOO, recruited from four different European clinics, were included in the analysis. Age, prostate specific antigen (PSA), international prostate symptom score (IPSS), quality of life (QOL), maximum urinary flow rate (Qmax) and total prostate and transitional zone volume were recorded. Clinical progression was defined as change from the mild-IPSS group into the moderate or severe group or the occurrence of urinary retention and need of surgery. Cumulative progression rate was 1, 7, 9 and 16% at 6, 12, 18 and 24 month, respectively, for the active group (Serona repens) as compared to 6, 13, 15 and 24% for the watchful waiting group. (P=0.03) significant improvements in the Qmax, IPSS and QOL were seen in the group receiving Serona repens. Serona repens significantly reduced the clinical progression rates in men with mild symptoms of BOO. It also led to improvements in urinary symptoms, QOL scores and urinary flow rates.
引用
收藏
页码:253 / 256
页数:3
相关论文
共 93 条
  • [1] Welsch G(2000)Quality-of-life impact of lower urinary tract symptom severity: results from the health professionals follow-up study Urology 59 245-250
  • [2] Weinger K(1998)Health-related quality of life associated with lower urinary tract symptoms in four countries Urology 51 428-436
  • [3] Barry MJ(2002)Predictors of progression in men with mild symptoms of bladder outlet obstruction J Urol 167 268-609
  • [4] Girman CJ(1995)Growing use of medicinal botanicals forces assessment by drug regulators JAMA 273 607-1553
  • [5] Jacobsen SJ(1998)Why patients use alternative medicine: results of a national study JAMA 279 1548-469
  • [6] Tsukamoto T(1994)The attitudes, behaviors, and beliefs of patients of conventional vs complementary (alternative) medicine J Clin Psychol 50 458-297
  • [7] Richard F(1995)Placebo controlled evaluation of the efficacy and tolerability of Permixon in benign prostatic hyperplasia after exclusion of placebo responders Clin Drug invest 9 291-21
  • [8] Garraway WM(1999)Permixon versus placebo. Results from multicenter trial CR Ther Pharmacol Clin 4 15-240
  • [9] Sagnier PP(1996)Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostatic hyperplasia: a randomized international study of 1098 patients Prostate 29 231-103
  • [10] Guess HA(1995)Comparative effects of alfuzosin versus Arch Esp Urol 48 97-965